Findings

What do systematic reviews say?

294 questions · 295 findings · 16 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 79 · 26.8%GRADE not reported 32 · 10.8%Very low 99 · 33.6%Low 55 · 18.6%Moderate 17 · 5.8%High 13 · 4.4%

Zuclopenthixol dihydrochloride vs haloperidol

Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Very low

Zuclopenthixol dihydrochloride vs haloperidol

Adverse effects: Clinically important general adverse effect (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs haloperidol

Death: Suicide and natural causes (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs haloperidol

Length of hospital stay · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs haloperidol

Mental state: Average endpoint general mental state score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs haloperidol

Leaving the study early · schizophrenia

It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with haloperidol (very low certainty).

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
RR 0.99 [0.72, 1.35]
2 studies · 141 participants
Very low

Zuclopenthixol dihydrochloride vs haloperidol

General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

CLOZAPINE + ARIPIPRAZOLE vs CLOZAPINE + HALOPERIDOL (Cipriani 2013)

Clinical response: no clinically significant response in mental state · people with treatment‐resistant schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CLOZAPINE + ARIPIPRAZOLE vs CLOZAPINE + HALOPERIDOL (Cipriani 2013)

Weight gain · people with treatment‐resistant schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CLOZAPINE + ARIPIPRAZOLE vs CLOZAPINE + HALOPERIDOL (Cipriani 2013)

Clinical response: mean score/change in global state · people with treatment‐resistant schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CLOZAPINE + ARIPIPRAZOLE vs CLOZAPINE + HALOPERIDOL (Cipriani 2013)

Mental state · people with treatment‐resistant schizophrenia

1 finding from 1 review

Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Low

CLOZAPINE + ARIPIPRAZOLE vs CLOZAPINE + HALOPERIDOL (Cipriani 2013)

Acceptability of treatment ‐ leaving the study early · people with treatment‐resistant schizophrenia

It is very uncertain whether CLOZAPINE + ARIPIPRAZOLE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + HALOPERIDOL (Cipriani 2013) (very low certainty).

1 finding from 1 review

Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes only
RR 1.27 [0.72, 2.22]
1 study · 106 participants
Very low

CLOZAPINE + ARIPIPRAZOLE vs CLOZAPINE + HALOPERIDOL (Cipriani 2013)

Service utilisation outcomes: hospital admission or days in hospital · people with treatment‐resistant schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CLOZAPINE + ARIPIPRAZOLE vs CLOZAPINE + HALOPERIDOL (Cipriani 2013)

Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · people with treatment‐resistant schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Droperidol vs haloperidol

Adverse effects ‐ cardiovascular ‐ hypotension · acute psychosis

Droperidol showed no clear difference in adverse effects ‐ cardiovascular ‐ hypotension compared with haloperidol (moderate certainty).

1 finding from 1 review

Droperidol for psychosis‐induced aggression or agitation 2016 · Cochrane Headline outcomes only
RR 2.8 [0.3, 26.49]
1 study · 228 participants
Moderate

Droperidol vs haloperidol

Adverse effects ‐ cardiovascular ‐ hypotension/desaturation · acute psychosis

Droperidol showed no clear difference in adverse effects ‐ cardiovascular ‐ hypotension/desaturation compared with haloperidol (low certainty).

1 finding from 1 review

Droperidol for psychosis‐induced aggression or agitation 2016 · Cochrane Headline outcomes only
RR 2.8 [0.12, 67.98]
1 study · 228 participants
Low

Droperidol vs haloperidol

Service use: person able to be discharged home · acute psychosis

1 finding from 1 review

Droperidol for psychosis‐induced aggression or agitation 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Droperidol vs haloperidol

Mental state: mean score by 13 days (Scale for Quantification of Psychotic Symptom Severity, high = poor) · acute psychosis

Droperidol showed no clear difference in mental state: mean score by 13 days (Scale for Quantification of… compared with haloperidol (low certainty).

1 finding from 1 review

Droperidol for psychosis‐induced aggression or agitation 2016 · Cochrane Headline outcomes only
MD 0.11
1 study · 40 participants
Low

Droperidol vs haloperidol

Economic: direct costs · acute psychosis

1 finding from 1 review

Droperidol for psychosis‐induced aggression or agitation 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Droperidol vs haloperidol

Tranquillisation or asleep · acute psychosis

Droperidol showed no clear difference in tranquillisation or asleep: tranquillised/sleep ‐ by around 30 minutes compared with haloperidol (high certainty).

1 finding from 1 review

Droperidol for psychosis‐induced aggression or agitation 2016 · Cochrane Headline outcomes only
RR 1.01 [0.93, 1.09]
1 study · 228 participants
High